Stewart, A. (1993) Discounted prices and prescribing costs for SSRIs. Personal Social Services Research Unit (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided)
<p>Prescribing costs account for about ten per cent of the NHS budget and are often the most visible aspect of specific courses of treatment. <p><p><p>Pharmaceutical companies may adopt aggressive pricing strategies to obtain initial prescriptions, especially where patients<p><p>are likely to remain on drug therapy for a substantial period of time. This can involve the offering of discounted prices to certain sectors e.g. hospitals to persuade them to initiate therapy using drugs that must then be paid for by the primary care sector at full price. <p><p><p>The example of antidepressants and particularly the SSRIs is used to show that such aggressive pricing strategies can result in an increased burden on the NHS, in terms of prescribing costs, even where the prescribing cost to the hospital sector is reduced substantially.
|Item Type:||Research report (external)|
|Divisions:||Faculties > Social Sciences > School of Social Policy Sociology and Social Research > Personal Social Services Research Unit|
|Depositing User:||R. Bass|
|Date Deposited:||20 May 2011 14:41|
|Last Modified:||20 May 2011 14:41|
|Resource URI:||https://kar.kent.ac.uk/id/eprint/27373 (The current URI for this page, for reference purposes)|